DRUG DISCOVERY PIPELINE
Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculosis mycobacteria, malaria, dengue, leishmania, bacterial infections, COVID-19 and RSV, spanning over early-stage discovery to late-stage clinical trials. Click here for FNDR's areas of research focus, our publications and information about our research programs.
TUBERCULOSIS
NONTUBERCULOUS MYCOBACTERIA
BACTERIAL INFECTIONS
FUNGAL INFECTIONS
MALARIA
INFLUENZA/COVID-19/RSV
DENGUE/ZIKA
CONTRACT SERVICES
FNDR performs various preclinical in vitro and animal studies for BSL-2 and BSL-3 bacterial, fungal and viral pathogens under a fee-for-service mode to test therapeutics, vaccines, and other items. Click here for more information.
​
Tuberculosis
Nontuberculous mycobacteria
Bacterial infections
Fungal infections
Viral Infections
COVID-19
Therapeutics Testing
Vaccines Testing
Virucidal Assays
In vitro Models
Animal Models
ACHIEVEMENTS
2
Drugs in Clinical Development
10+
Ongoing Innovation Projects on Platform Technologies.
3
Repurposed drugs under development
300+
Contract Research Projects Completed
12
New Drugs in Preclinical Development
100+
Research and Development Partners
LATEST NEWS
Positive results from Phase 2A clinical trial of TBA-7371, a new drug candidate for tuberculosis
29 November 2023
Foundation for Neglected Disease Research (FNDR) is proud to announce that its partners, Bill & Melinda Gates Medical Research Institute and TB Alliance, have successfully completed the Phase 2A Early Bactericidal Activity clinical trial of TBA-7371, a novel DprE1 inhibitor for the treatment of tuberculosis. The results were presented at the 2023 Union World Conference on Lung Health in Paris. TBA-7371 was well tolerated and showed significant dose-dependent bactericidal activity with 14 days of treatment in patients with drug-susceptible pulmonary tuberculosis. TBA-7371 could have significant potential in the treatment of TB.